Alkaline phosphatase formulations
US-12048735-B2 · Jul 30, 2024 · US
US9486486B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9486486-B2 |
| Application number | US-201113997022-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 22, 2011 |
| Priority date | Dec 22, 2010 |
| Publication date | Nov 8, 2016 |
| Grant date | Nov 8, 2016 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention relates to a novel bacterial strain isolated and characterized from groundwater. The invention also relates to bacterial extracts and to the therapeutic use of same, notably in the context of the treatment of inflammations.
Opening claim text (preview).
The invention claimed is: 1. A composition comprising a bacterial extract as an active ingredient and a pharmaceutically acceptable carrier, wherein the bacterial extract is obtained from a suspension of bacteria, and wherein said bacteria of the suspension is a nonpathogenic Gram-negative bacterium belonging to the class Betaproteobacteria, subfamily Neisseriaceae, and characterized in that a nucleotide sequence of a 16S rRNA gene of said bacterium includes sequence SEQ ID NO: 1. 2. The composition according to claim 1 , wherein said bacterium of the bacterial extract is the bacterium deposited with the CNCM on Apr. 8, 2010, under the reference 1-4290. 3. Bacterial extract obtained from a suspension of bacteria, wherein said bacteria of the suspension is a nonpathogenic Gram-negative bacterium belonging to the class Betaproteobacteria, subfamily Neisseriaceae, and characterized in that a nucleotide sequence of a 16S rRNA gene of said bacterium includes sequence SEQ ID NO: 1, and wherein the bacterial extract is obtained after treatment of said bacterial suspension in such a way as to eliminate intracellular components. 4. Bacterial extract according to claim 3 , wherein said intracellular components include at least nucleic acids. 5. Bacterial extract according to claim 3 , wherein it includes a fraction E0 comprising at least membrane proteins, periplasmic proteins and proteins arising from the flagellum. 6. Bacterial extract according to claim 5 , wherein said membrane proteins consist of porins, OmpA, lipopolysaccharides and/or lipoproteins. 7. Bacterial extract according to claim 3 , wherein it includes a fraction SO comprising at least secreted peptides and proteins and secondary metabolites. 8. Bacterial extract according to claim 3 , wherein it includes a fraction ESO comprising at least fraction E0 and fraction SO. 9. Bacterial extract according to claim 8 , wherein said fraction ESO has a protein profile, obtained by SDS-PAGE, which includes three principal bands corresponding to molecular weights ranging between 30 kDa and 36 kDa, 41 kDa and 45 kDa, and 47 kDa and 51 kDa, respectively. 10. Composition comprising at least, as an active ingredient, a bacterial extract according to claim 3 . 11. Composition according to claim 10 , for the treatment of gastrointestinal and oral inflammatory diseases. 12. Composition according to claim 11 , wherein said gastrointestinal and oral inflammatory diseases consist of Crohn's disease, colitis or periodontitis. 13. Composition according claim 10 , wherein further comprising a pharmaceutically acceptable carrier. 14. Method of activating TLR2, TLR4 and/or TLR5 which comprises contacting cells expressing TLR2, TLR4 and/or TLR5 with a bacterial extract of claim 1 . 15. Method of inhibiting PAR2 activation, which comprises contacting cells expressing PAR2 with a bacterial extract of claim 7 .
Immunomodulators · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title
Bacteria (therapeutic use of a bacterial protein A61K38/00) · CPC title
Neisseria · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.